Valerio Therapeutics Société anonyme (EPA:ALVIO)

Market Cap	199.78M +1,865.9%
Revenue (ttm)	2.57M +43.5%
Net Income	-4.90M
EPS	-0.02
Shares Out	499.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	782,718
Open	0.4500
Previous Close	0.4500
Day's Range	0.4000 - 0.4550
52-Week Range	0.0532 - 0.5340
Beta	1.80
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody– drug conjugates, and chimeric antigen receptors. The company was formerly known as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 25
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVIO

Financial Performance

In 2025, EPA:ALVIO's revenue was 2.57 million, an increase of 43.50% compared to the previous year's 1.79 million. Losses were -4.90 million, -79.53% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 13, 2026

Data Sources Report a data error